youtube_live
Q3 2026 earnings • released • EPS beat +24.59% • Revenue beat +19.41%
See resultschevron_right
BBIO:NASDAQ
BridgeBio Pharma Inc
$74.95
arrow_upward
+5.97%(+4.22) 1D
$74.47
arrow_downward
-0.64% (-0.48)bedtimeAfter hours
Closed: Oct 30, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BBIO...
Open
$72.85
High
$75.85
Low
$71.90
Mkt. cap
14.65B
Avg. vol.
2.90M
Volume
5.77M
52-wk high
$93.42
52-wk low
$60.23
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
Open
$72.85
High
$75.85
Low
$71.90
Mkt. cap
14.65B
Avg. vol.
2.90M
Volume
5.77M
52-wk high
$93.42
52-wk low
$60.23
EPS
-$3.57
Beta
0.97
Shares outstanding
195.49M
No. of employees
1K
News stories
From web sources and news partners
Investing.com
·
1 day ago
UBS reiterates BridgeBio stock rating on strong Attruby sales
Yahoo Finance
·
1 day ago
BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary
TradingView
·
1 day ago
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
Benzinga
·
1 day ago
BridgeBio Pharma Q3 2026 Earnings Call Transcript
About BridgeBio Pharma Inc
CEONeil Kumar
Employees1K
Founded2015
HeadquartersPalo Alto, California, United States
SectorBiotechnology
Websitebridgebio.com
Analyst ratings
Based on 18 analysts giving stock ratings to BBIO in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for BBIO in the last 3 months.
Highest
Current $74.95
$156.00 (+108.14%)
Average
$109.56 (+46.18%)
Lowest
$88.00 (+17.41%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Jason Zemansky Bank of America Securities | Buy | Maintained | - | - | 10/30/2026 |
Sean Laaman Morgan Stanley | Buy | Reiterated | $88.00 | +17.4% | 10/30/2026 |
Luca Issi RBC Capital | Buy | Maintained | $100.00 | +33.4% | 10/30/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | $100.00 | +33.4% | 10/30/2026 |
Joshua Schimmer Cantor Fitzgerald | Buy | Reiterated | $110.00 | +46.8% | 10/29/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $130.00 | +73.4% | 10/30/2026 |
Joon Lee UBS | Buy | Maintained | $92.00 | +22.7% | 10/30/2026 |
Biren Amin Piper Sandler | Buy | Maintained | $120.00 | +60.1% | 10/30/2026 |
Derek Archila Wells Fargo | Buy | Reiterated | $102.00 | +36.1% | 10/30/2026 |
Eric Joseph Citi | Hold | Maintained | $91.00 | +21.4% | 10/30/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $102.00 | +36.1% | 10/15/2026 |
Ram Selvaraju H.C. Wainwright | Buy | Reiterated | $120.00 | +60.1% | 10/15/2026 |
Whitney Ijem Canaccord Genuity | Buy | Maintained | $106.00 | +41.4% | 10/06/2026 |
Eliana Merle Barclays | Buy | Maintained | $156.00 | +108.1% | 10/07/2026 |
Myles Minter William Blair | Buy | Reiterated | - | - | 10/06/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $110.00 | +46.8% | 08/31/2026 |
Andrew Tsai Jefferies | Buy | Maintained | $110.00 | +46.8% | 08/31/2026 |
Anupam Rama J.P. Morgan | Buy | Reiterated | $111.00 | +48.1% | 08/12/2026 |
Danielle Brill Truist Financial | Buy | Maintained | $107.00 | +42.8% | 08/12/2026 |
Unknown Analyst Wells Fargo | Buy | Reiterated | $102.00 | +36.1% | 08/11/2026 |
Tiago Fauth Raymond James | Buy | Maintained | $98.00 | +30.8% | 06/17/2026 |
Martin Auster Raymond James | Hold | Downgraded | - | - | 05/26/2026 |
Unknown Analyst Citi | Hold | Initiated | - | - | 05/19/2026 |
William Pickering Bernstein | Buy | Reiterated | $114.00 | +52.1% | 05/08/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $116.00 | +54.8% | 05/08/2026 |
Matt Phipps William Blair | Buy | Reiterated | - | - | 05/02/2026 |
Lisa Walter RBC Capital | Buy | Initiated | $100.00 | +33.4% | 04/08/2026 |
Trevor Allred Oppenheimer | Buy | Maintained | $81.00 | +8.1% | 02/25/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$0.42 / -$0.56
+24.59%beat
arrow_upward
Revenue / Est. (USD)
353.17M / 295.75M
+19.41%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 120.70M | 154.18M | 194.52M | 243.68M |
Cost of goods sold | 6.56M | 8.11M | 9.94M | 15.05M |
Cost of revenue | 6.56M | 8.11M | 9.94M | 15.05M |
Research and development expenses | 112.87M | 116.42M | 126.64M | 149.45M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 137.62M | 158.08M | 163.90M | 186.26M |
Operating expense | 250.50M | 274.50M | 290.53M | 335.71M |
Total operating expenses | 257.06M | 282.61M | 300.47M | 350.76M |
Operating income | -136.36M | -128.43M | -105.96M | -107.08M |
Other non operating income | 16.46M | 11.82M | 4.25M | 5.59M |
EBT including unusual items | -186.48M | -194.76M | -166.56M | -155.89M |
EBT excluding unusual items | -177.64M | -183.62M | -166.56M | -155.89M |
Income tax expense | -1.54M | -120.00K | - | - |
Effective tax rate | 0.83% | 0.06% | - | - |
Other operating expenses | - | - | - | - |
Net income | -182.74M | -192.86M | -164.04M | -152.22M |
Net profit margin | -151.40% | -125.09% | -84.33% | -62.47% |
Earnings per share | -0.72 | -0.94 | -0.84 | -0.78 |
Interest and investment income | 6.24M | 4.33M | 6.25M | 6.66M |
Interest expense | -48.15M | -50.31M | -52.82M | -54.62M |
Net interest expenses | -41.91M | -45.98M | -46.57M | -47.96M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -134.96M | -127.00M | -104.77M | -106.03M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events